RION Appoints Alisa Lask as Chief Commercial Officer

Rhea-AI Summary

RION, a biotechnology company based in Rochester, Minnesota, has appointed Alisa Lask as Chief Commercial Officer. Lask brings extensive experience from leadership roles at major firms including Galderma and Allergan, aiming to commercially leverage RION's groundbreaking exosome therapeutics. The company currently has two active FDA registrations and focuses on innovative biologic platforms for regenerative medicine. Dr. Atta Behfar, RION's founder, expressed confidence in Lask's strategic vision to drive growth in both therapeutic and aesthetic sectors.

Positive

• Appointment of Alisa Lask as Chief Commercial Officer to enhance commercialization efforts.
• Proven track record of Lask in driving revenue and profitability in previous roles.
• Two active FDA registrations suggest regulatory progress and future commercial opportunities.

Negative

• None.

- Alisa Lask to lead commercialization of the first off-the-shelf exosome therapeutic platform

- Two active FDA registrations

ROCHESTER, Minn.--(BUSINESS WIRE)-- RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer.

“Alisa brings an exemplary track record gained through both global and U.S. leadership roles at Galderma, Allergan, Zimmer-Biomet, and Eli Lilly and Company, showing significant capability to spearhead commercial strategies to create world-class aesthetic and therapeutic product franchises,” said Dr. Atta Behfar, Founder of RION. “She has proven skills in leading large commercial organizations, launching brands, driving revenue and profitability while fostering a high-performing organization. We are pleased to have an experienced industry leader who can help build a strong commercial infrastructure commensurate with the breakthrough potential of our proprietary Regenerative Exosomes.”

“I am honored for the opportunity to join RION, especially given the company’s breakthrough technology in which I see clear potential,” said Lask. “Regenerative medicine is the future and will garner meaningful adoption with advancements in technology. I look forward to introducing the first truly novel off-the-shelf regenerative medicine since the category was created.”

“The Board and I have great confidence Alisa has the strategic vision, extensive industry knowledge, and operational experience needed to drive growth and lead RION to continued success,” continued Dr. Behfar. “She has a proven track record of accomplishments, industry relationships, and unparalleled experience that bring great benefit to our company’s aesthetics and therapeutic portfolio. Alisa also brings a personal style fully aligned with our values and culture, making her a natural fit for the team.”

Alisa holds a Master of Business Administration from the University of Michigan and a bachelor’s degree in marketing from Miami University, Oxford, Ohio. She currently serves on the Board of Directors for Collpant (Nasdaq: CLGN) and Nephros (Nasdaq: NEPH).

About RION

RION is a clinical-stage regenerative medicine company focused on developing innovative exosome therapeutics that are clinically impactful and broadly accessible. RION has developed Purified Exosome Product™ (PEP™), an innovative biologic platform that harnesses the therapeutic power of exosomes for regenerative medicine. RION was established in 2017 through the Mayo Clinic Employee Entrepreneurial Program and is headquartered in Rochester, Minnesota. For more information, visit www.riontx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220114005067/en/

Company Inquiries: Jodi Brichan, media@riontx.com

Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091

Source: RION

FAQ

Who is Alisa Lask and what role has she been appointed to at RION?

Alisa Lask has been appointed as Chief Commercial Officer at RION, focusing on the commercialization of their exosome therapeutic platform.

What is the significance of RION's two active FDA registrations?

RION's two active FDA registrations indicate ongoing regulatory progress, which could lead to future product approvals and market entry.

What qualifications does Alisa Lask bring to her new role at RION?

Alisa Lask holds an MBA from the University of Michigan and has extensive leadership experience in the biotechnology and pharmaceutical industries.

How does RION plan to leverage Alisa Lask's experience for growth?

RION aims to utilize Alisa Lask's track record in launching brands and driving profitability to enhance its commercial strategies and strengthen its market position.